News | July 29, 2011

Oxygen Biotherapeutics, Aurum Biosciences Explore Imaging, Therapeutic Uses of Oxycyte PFC

July 29, 2011 — Oxygen Biotherapeutics Inc. and privately held Aurum Biosciences Ltd. of Glasgow, Scotland, have signed a letter of intent (LOI) to conduct preclinical research for imaging and therapeutic intervention of acute ischemic stroke. Aurum, using Oxygen’s proprietary Oxycyte PFC (perfluorocarbon) emulsion in combination with Aurum’s proprietary Glasgow Oxygen Level Dependent (GOLD) magnetic resonance imaging (MRI) techniques, will conduct the research.  

The intent is to better delineate which tissue has been damaged from a stroke, and to determine the effectiveness of the treatment being provided to the model. Per the LOI, Aurum will seek funding for this research.

An ischemic stroke occurs when a blood vessel that carries oxygen and nutrients to the brain is blocked by a clot. When that happens, part of the brain cannot get the blood and, therefore, the oxygen it needs, so it starts to die. 

According to the American Stroke Association (ASA), approximately 795,000 Americans each year suffer a new or recurrent stroke. That means, on average, a stroke occurs every 40 seconds. Stroke kills more than 137,000 people a year in the United States alone and is the third leading cause of death behind diseases of the heart and cancer. On average, someone dies of stroke every four minutes. About 40 percent of stroke deaths occur in males, and 60 percent in females.

According to The Stroke Association, an estimated 150,000 people have a stroke in the United Kingdom each year, accounting for around 53,000 deaths annually. Stroke is the third most common cause of death in England and Wales, after heart disease and cancer. It accounts for 9 percent of all deaths in men and 13 percent of deaths in women in the United Kingdom.

For more information:

Related Content

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media | January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
GE Healthcare, Optison ultrasound contrast agent, FDA labeling change, cardiac shunts, intra-arterial injection
Technology | Contrast Media | October 04, 2016
GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has approved a label change for the ultrasound...
Overlay Init